Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 5, 2004, Pages 2078-2084

  Ahrén, Bo ^a,e   Landin Olsson, Mona ^a   Jansson, Per Anders ^b   Svensson, Maria ^c   Holmes, David ^d   Schweizer, Anja ^d  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d NOVARTIS PHARMA AG   (Switzerland)

^e B11 Biomedical Centre   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

[1 [(3 HYDROXY 1 ADAMANTYL)AMINO]ACETYL] 2 CYANOPYRROLIDINE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PEPTIDE HYDROLASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET THERAPY; DIZZINESS; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FEMALE; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESPONSE; MALE; MEAL; METABOLIC REGULATION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PRURITUS;

ADAMANTANE; AGED; ANTIGENS, CD26; BLOOD GLUCOSE; BODY WEIGHT; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; EATING; ENZYME INHIBITORS; FEMALE; GLUCAGON; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; LIPIDS; MALE; MIDDLE AGED; PYRROLIDINES;

EID: 2442482515     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031907     Document Type: Article

References (30)

1. Ahrén B 1998 Glucagon-like peptide 1 (GLP-1) - a gut hormone of potential interest in the treatment of diabetes. Bioessays 20:642-651
2. Drucker DJ 2002 Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122:531-544
3. Holst JJ 2002 Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabet Metab Res Rev 18:430-441
4. Egan JM, Bulotta A, Hui H, Perfetti R 2003 GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet β cells. Diabet Metab Res Rev 19:115-123
5. Gutniak M, Ørskov C, Holst J, Ahrén B, Efendic S 1992 Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322
6. Zander M, Madsbad S, Madsen JL, Holst JJ 2002 Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830
7. Juntti-Berggren L, Pigon J, Karpe F, Hamsten A, Gutniak M, Vignati L, Efendic S 1996 The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 19:1200-1206
8. Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B 1997 GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care 20:1874-1879
9. Cherrington AD, Stevenson RW, Steiner KE, Davis MA, Myers SR, Adkins BA, Abumrad NN, Williams PE 1987 Insulin, glucagon, and glucose as regulators of hepatic glucose uptake and production in vivo. Diabet Metab Rev 3:307-332
10. Unger RH, Aquilar-Parada E, Muller WA, Eisentraut AM 1970 Studies of pancreatic a cell function in normal and diabetic subjects. J Clin Invest 49:837-848
11. Muller WA, Faloona GR, Aquilar-Parada E, Unger RH 1970 Abnormal α-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 283:109-115
12. Dobbs R, Sakurai H, Sasaki H, Faloona G, Valverde I, Baetens D, Orci L, Unger R 1975 Glucagon: role in the hyperglycemia of diabetes mellitus. Science 187:544-547
13. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA 2000 Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053-4059
14. Ahrén B, Larsson H 2001 Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 44:1998-2003
15. Mentlein R 1999 Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 85:9-24
16. Deacon CF, Johnsen AH, Holst JJ 1995 Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957
17. Holst JJ, Deacon CF 1998 Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663-1670
18. Pedersen RA, White HA, Schlenzig D, Pauly RP, McIntosh CHS, Dermuth HU 1998 Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidylpeptidase IV inhibitor isoleucine thiazolidide. Diabetes 47:1253-1258
19. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X 1999 Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331
20. Ahrén B, Holst JJ, Mårtensson H, Balkan B 2000 Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 404:239-245
21. Kvist Reimer M, Holst JJ, Ahrén B 2002 Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146:717-727
22. Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Båvenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D 2002 Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type 2 diabetes. Diabetes Care 25:869-875
23. Villhauer EB, Brinkman JA, Naderi GB, Burkey BNF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE 2003 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46:2774-2789
24. Kieffer TJ, McIntosh CH, Pederson RA 1995 Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596
25. Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, Schmidt K, Bagchi A, Griffin PR, Thornberry NA, Sinha Roy R 2003 The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem 278:22418-22423
26. Nauck MA, Heimesatt MM, Ørskov C, Holst JJ, Ebert, R, Creutzfeldt W 1993 Preserved incretin activity of glucagon-like peptide 1[7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 91:301-307
27. Filipsson K, Tornøe K, Holst J, Ahrén B 1997 Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans. J Clin Endocrinol Metab 82:3093-3098
28. Hansotia T, Baggio L, Yamada Y, Tsukiyama K, Preitner F, Thorens B, Seino Y, Drucker D 2003 Combined genetic disruption of dual incretin receptor signaling pathways reveals novel glucose lowering properties of DPP-IV inhibitors in mice. Diabetes 52(Suppl 1):A77
29. Meier JJ, Gallwitz B, Siepmann N, Hoist JJ, Deacon CF, Schmidt WE, Nauck MA 2003 Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucason secretion in healthy human subjects at euglycaemia. Diabetologia 46:798-801
30. Ahrén B, Larsson H, Holst JJ 1997 Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478